HCPCS Level II drug code
J9260 — Injection, methotrexate sodium, 50 mg
In short
J9260 is the HCPCS Level II code for injection, methotrexate sodium, 50 mg. CMS assigns NDCs for Methotrexate Sodium to it. One billing unit is 50 mg. The Medicare Part B payment limit is $2.909 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, methotrexate sodium, 50 mg
- Short descriptor
- Inj methotrexate sodium 50mg
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Apr 1, 2024
The billing unit is read from the descriptor. Confirm it against the CMS file before billing.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 50 mg. For example, 5000 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
NDCs billed under J9260
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 18 NDCs to J9260 for Methotrexate Sodium. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Methotrexate Sodium | 00143-9367-01 | Hikma Pharmaceuticals USA Inc. | 1 | 20 |
| Methotrexate Sodium | 00143-9519-10 | Hikma Pharmaceuticals USA Inc. | 10 × 2 | 10 |
| Methotrexate Sodium | 00143-9830-01 | Hikma Pharmaceuticals USA Inc. | 1 | 20 |
| Methotrexate Sodium | 00703-3671-01 | Teva Parenteral Medicines, Inc. | 2 | 1 |
| Methotrexate Sodium | 00703-3675-01 | Teva Parenteral Medicines, Inc. | 10 | 5 |
| Methotrexate Sodium | 00703-3678-01 | Teva Parenteral Medicines, Inc. | 40 | 20 |
| Methotrexate Sodium | 00703-3678-81 | Teva Parenteral Medicines, Inc. | 40 | 20 |
| Methotrexate Sodium | 16729-0277-03 | ACCORD HEALTHCARE INC | 10 | 5 |
| Methotrexate Sodium | 16729-0277-30 | Accord Healthcare Inc | 2 | 1 |
| Methotrexate Sodium | 16729-0277-35 | Accord Healthcare Inc | 40 | 20 |
| Methotrexate Sodium | 61703-0124-40 | Pfizer Inc | 40 | 20 |
| Methotrexate Sodium | 61703-0161-05 | Pfizer Inc | 5 × 2 | 5 |
| Methotrexate Sodium | 61703-0350-10 | Pfizer Inc | 5 × 2 | 5 |
| Methotrexate Sodium | 61703-0350-38 | Pfizer Inc | 5 × 2 | 5 |
| Methotrexate Sodium | 61703-0408-25 | Pfizer Inc | 40 | 20 |
| Methotrexate Sodium | 61703-0408-41 | Pfizer Inc | 40 | 20 |
| Methotrexate Sodium | 63323-0122-50 | FreseniUS Kabi USA, LLC | 1 | 20 |
| Methotrexate Sodium | 63323-0123-10 | FreseniUS Kabi USA, LLC | 10 | 5 |
J9260: common questions
- Is J9260 a CPT code?
- No. J9260 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J9260?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 18 NDCs under J9260, for Methotrexate Sodium. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J9260?
- $2.909 per 50 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J9260?
- One unit of J9260 is 50 mg, as stated in the code's descriptor. Units to report = dose given ÷ 50 mg. J-code billing units.